Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men

被引:36
作者
Bravenboer, N
Holzmann, PJ
ter Maaten, JC
Stuurman, LM
Roos, JC
Lips, P
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, NL-1007 MB Amsterdam, Netherlands
[2] Acad Hosp, Dept Internal Med, Groningen, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Nucl Med, NL-1007 MB Amsterdam, Netherlands
关键词
growth hormone; growth hormone deficiency; BMD; bone metabolism; histomorphometry;
D O I
10.1359/JBMR.050613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Long-term GH treatment in GH-deficient men resulted in a continuous increase in bone turnover as shown by histomorphometry. BMD continuously increased in all regions of interest, but more in the regions with predominantly cortical bone. Introduction: Adults with growth hormone (GH) deficiency have reduced rates of bone turnover and subnormal BMD. GH treatment is effective in enhancing bone turnover as shown by biochemical markers and bone histomorphometric studies. However, it is uncertain whether long-term treatment will result in higher bone mass. In this study, we present BMD and histomorphometric data on 5 years of GH treatment in GH-deficient men. Materials and Methods: Thirty-eight adult men with childhood onset GH deficiency (20-35 years) were included in the study. Twenty-six of these had multiple pituitary hormone deficiencies and were on stable conventional hormone replacement. BMC (total body) and BMD (lumbar spine and hip) were measured before and after 1, 2, 3, 4, and 5 years of treatment. BMD in various regions of the total body was calculated by computer software (head, trunk, arms, and legs). Transiliac bone biopsies were obtained before and after 1 and 5 years of GH treatment. Results: Total body BMC increased 18% after 5 years of treatment. This increase was observed in all regions of interest: head, 13.7%; trunk, 27.8%; arms, 24.4%; legs, 13.8%. BMD also increased in all separately measured regions: lumbar spine, 9%; femoral neck, 11%; femoral trochanter, 16%. Lumbar spine area significantly increased (p = 0.0002). Histomorphometric data showed increased osteoid surface (p < 0.02), osteoid volume (p < 0.01), and activation frequency (p < 0.006), but trabecular bone volume did not increase significantly. Qualitative assessment of the cortical bone showed endosteal and periosteal bone formation. Conclusions: In conclusion, GH considerably increases BMC after long-term treatment. The combination of BMD and histomorphometric data suggests that GH has a greater effect on cortical than on trabecular bone.
引用
收藏
页码:1778 / 1784
页数:7
相关论文
共 27 条
  • [1] BODY-COMPOSITION, BONE METABOLISM, AND HEART STRUCTURE AND FUNCTION IN GROWTH-HORMONE (GH)DEFICIENT ADULTS BEFORE AND AFTER GH REPLACEMENT THERAPY AT LOW-DOSES
    AMATO, G
    CARELLA, C
    FAZIO, S
    LAMONTAGNA, G
    CITTADINI, A
    SABATINI, D
    MARCIANOMONE, C
    SACCA, L
    BELLASTELLA, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (06) : 1671 - 1676
  • [2] Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379
  • [3] Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD
    Baroncelli, GI
    Bertelloni, S
    Sodini, F
    Saggese, G
    [J]. CLINICAL ENDOCRINOLOGY, 2004, 60 (02) : 175 - 184
  • [4] THE EFFECTS OF PROLONGED GROWTH-HORMONE REPLACEMENT ON BONE METABOLISM AND BONE-MINERAL DENSITY IN HYPOPITUITARY ADULTS
    BESHYAH, SA
    KYD, P
    THOMAS, E
    FAIRNEY, A
    JOHNSTON, DG
    [J]. CLINICAL ENDOCRINOLOGY, 1995, 42 (03) : 249 - 254
  • [5] The skeletal structure of insulin-like growth factor I-deficient mice
    Bikle, D
    Majumdar, S
    Laib, A
    Powell-Braxton, L
    Rosen, C
    Beamer, W
    Nauman, E
    Leary, C
    Halloran, B
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (12) : 2320 - 2329
  • [6] The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men
    Bravenboer, N
    Holzmann, P
    DeBoer, H
    Roos, JC
    VanderVeen, EA
    Lips, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (06) : 1818 - 1822
  • [7] Parathyroid hormone for treatment of osteoporosis
    Crandall, C
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (20) : 2297 - 2309
  • [8] Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers
    deBoer, H
    Blok, GJ
    PoppSnijders, C
    Stuurman, L
    Baxter, RC
    vanderVeen, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (04) : 1371 - 1377
  • [9] DEBOER H, 1994, LANCET, V343, P1645, DOI 10.1016/S0140-6736(94)93104-6
  • [10] DEBOER H, 1994, J BONE MINER RES, V9, P1319